Steven RPh - Werewolf Therapeutics Chief Officer
| HOWL Stock | USD 0.62 0.02 2.47% |
Executive
Steven RPh is Chief Officer of Werewolf Therapeutics
| Age | 65 |
| Address | 200 Talcott Ave, Watertown, MA, United States, 02472 |
| Phone | 617 952 0555 |
| Web | https://werewolftx.com |
Werewolf Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.4075) % which means that it has lost $0.4075 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.2243) %, meaning that it created substantial loss on money invested by shareholders. Werewolf Therapeutics' management efficiency ratios could be used to measure how well Werewolf Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.67. The value of Return On Capital Employed is expected to slide to -0.8. At this time, Werewolf Therapeutics' Net Tangible Assets are quite stable compared to the past year. Non Current Assets Total is expected to rise to about 17.5 M this year, although the value of Non Currrent Assets Other will most likely fall to about 349.6 K.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Blake Aftab | Adicet Bio | 45 | |
| Robert MD | Lite Strategy | 72 | |
| Julie MD | Adicet Bio | N/A | |
| Qasim MD | IO Biotech | 54 | |
| Anne Frese | Lite Strategy | N/A | |
| Faical Miyara | IO Biotech | N/A | |
| Joseph Casper | NRX Pharmaceuticals | 75 | |
| Matthew Duffy | NRX Pharmaceuticals | 63 | |
| Daniel Mannix | IO Biotech | N/A | |
| Michael Abrams | NRX Pharmaceuticals | 56 | |
| Jedd Comiskey | OUTLOOK THERAPEUTICS INC | N/A | |
| KerriAnn Millar | Cue Biopharma | 54 | |
| Cory Ellspermann | INmune Bio | N/A | |
| KerriAnn CPA | Cue Biopharma | 55 | |
| Terry Dagnon | OUTLOOK THERAPEUTICS INC | 62 | |
| Robert Petit | OS Therapies Incorporated | 65 | |
| Gerald Commissiong | OS Therapies Incorporated | 44 | |
| Heidi MPH | Spruce Biosciences Common | N/A | |
| Marjan PharmD | IO Biotech | N/A | |
| Amy MBA | IO Biotech | 56 | |
| P Ramtin | Spruce Biosciences Common | N/A | |
Management Performance
| Return On Equity | -1.22 | ||||
| Return On Asset | -0.41 |
Werewolf Therapeutics Leadership Team
Elected by the shareholders, the Werewolf Therapeutics' board of directors comprises two types of representatives: Werewolf Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Werewolf. The board's role is to monitor Werewolf Therapeutics' management team and ensure that shareholders' interests are well served. Werewolf Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Werewolf Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Randi MD, Chief Officer | ||
| Timothy CPA, Treasurer CFO | ||
| Cynthia SeidelDugan, Chief Officer | ||
| Ellen MBA, Chief Officer | ||
| Daniel Hicklin, CEO, Founder | ||
| William Winston, Senior Research | ||
| Chulani Karunatilake, Chief Officer | ||
| Michael Urban, Principal Officer | ||
| Steven RPh, Chief Officer | ||
| Reid Leonard, Chief Officer |
Werewolf Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Werewolf Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.22 | ||||
| Return On Asset | -0.41 | ||||
| Current Valuation | 3.63 M | ||||
| Shares Outstanding | 48.54 M | ||||
| Shares Owned By Insiders | 5.61 % | ||||
| Shares Owned By Institutions | 41.14 % | ||||
| Number Of Shares Shorted | 2.42 M | ||||
| Price To Earning | 0.84 X | ||||
| Price To Book | 1.08 X | ||||
| Price To Sales | 52.22 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Werewolf Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in private. For more information on how to buy Werewolf Stock please use our How to buy in Werewolf Stock guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Werewolf Therapeutics. Market participants price Werewolf higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Werewolf Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Investors evaluate Werewolf Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Werewolf Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Werewolf Therapeutics' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Werewolf Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Werewolf Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Werewolf Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.